

Inaki F Troconiz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8952769/inaki-f-troconiz-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

163
papers

3,260
citations

29
h-index

50
g-index

181
ext. papers

3,700
ext. citations

4.6
avg, IF

5.19
L-index

#	Paper	IF	Citations
163	IMI2-PainCare-BioPain-RCT1: study protocol for a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by peripheral nerve excitability testing (NET). <i>Trials</i> , 2022 , 23, 163	2.8	0
162	Pharmacometrics in Drug Discovery and Development 2022 , 918-927		
161	Pharmacometrics: Definition and History 2022 , 933-939		
160	Pharmacometrics: Disease Progression Modeling 2022 , 939-945		
159	Enteric reabsorption processes and their impact on drug pharmacokinetics. <i>Scientific Reports</i> , 2021 , 11, 5794	4.9	2
158	Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model. <i>Journal of Nanobiotechnology</i> , 2021 , 19, 102	9.4	15
157	IMI2-PainCare-BioPain-RCT3: a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by electroencephalography (EEG). <i>Trials</i> , 2021 , 22, 404	2.8	1
156	The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives. <i>Pharmaceutics</i> , 2021 , 13,	6.4	3
155	Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration. <i>Frontiers in Pharmacology</i> , 2021 , 12, 705443	5.6	1
154	A quantitative systems pharmacology model for acute viral hepatitis B. <i>Computational and Structural Biotechnology Journal</i> , 2021 , 19, 4997-5007	6.8	0
153	Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and η -PD-1. <i>British Journal of Cancer</i> , 2021 , 124, 1275-1285	8.7	0
152	Untangling Absorption Mechanisms and Variability in Bioequivalence Studies Using Population Analysis.. <i>Pharmaceutical Research</i> , 2021 , 38, 2047	4.5	
151	Pharmacokinetic Profiles Determine Optimal Combination Treatment Schedules in Computational Models of Drug Resistance. <i>Cancer Research</i> , 2020 , 80, 3372-3382	10.1	4
150	Machine Learning Analysis of Individual Tumor Lesions in Four Metastatic Colorectal Cancer Clinical Studies: Linking Tumor Heterogeneity to Overall Survival. <i>AAPS Journal</i> , 2020 , 22, 58	3.7	7
149	Disease pharmacokinetic-pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA-based therapies. <i>British Journal of Pharmacology</i> , 2020 , 177, 3168-3182	8.6	3
148	A Quantitative Systems Pharmacology Model for the Key Interleukins Involved in Crohn's Disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020 , 372, 299-307	4.7	5
147	Modelling of neutrophil dynamics in children receiving busulfan or treosulfan for haematopoietic stem cell transplant conditioning. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1537-1549	3.8	1

146	Predicting circulating biomarker response and its impact on the survival of advanced melanoma patients treated with adjuvant therapy. <i>Scientific Reports</i> , 2020 , 10, 7478	4.9	2
145	Model-Informed Dose Selection for Xentuzumab, a Dual Insulin-Like Growth Factor-I/II-Neutralizing Antibody. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 597-606	6.1	6
144	Drug Exposure to Establish Pharmacokinetic-Response Relationships in Oncology. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 123-135	6.2	1
143	Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2R2Rdifluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer. <i>Clinical and Translational Science</i> , 2020 , 13, 608-617	4.9	1
142	Beyond Deterministic Models in Drug Discovery and Development. <i>Trends in Pharmacological Sciences</i> , 2020 , 41, 882-895	13.2	9
141	Semi-Mechanistic Pharmacokinetic Modeling of Lipid Core Nanocapsules: Understanding Quetiapine Plasma and Brain Disposition in a Neurodevelopmental Animal Model of Schizophrenia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020 , 375, 49-58	4.7	2
140	Finding the Dose for Ceftolozane-Tazobactam in Critically Ill Children with and without Acute Kidney Injury. <i>Antibiotics</i> , 2020 , 9,	4.9	4
139	Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies. <i>AAPS Journal</i> , 2019 , 21, 23	3.7	2
138	Immune network for viral hepatitis B: Topological representation. <i>European Journal of Pharmaceutical Sciences</i> , 2019 , 136, 104939	5.1	1
137	Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling. <i>PLoS ONE</i> , 2019 , 14, e0215970	3.7	2
136	Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1670-1683	3.8	6
135	Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 363-374	6.2	10
134	B-PRECISE-01 Study: A phase Ib trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab and fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS1101-TPS1101	2.2	2
133	Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 835-857	6.2	111
132	Pharmacokinetic and Pharmacodynamic Modelling in Anaesthesia 2019 , 14-28		
131	A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. <i>Leukemia Research</i> , 2019 , 76, 1-10	2.7	9
130	A new immune-nanoplatform for promoting adaptive antitumor immune response. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019 , 17, 13-25	6	9
129	Computational disease model of phenobarbital-induced acute attacks in an acute intermittent porphyria mouse model. <i>Molecular Genetics and Metabolism</i> , 2019 , 128, 367-375	3.7	1

128	Colo-Pro: a pilot randomised controlled trial to compare standard bolus-dosed cefuroxime prophylaxis to bolus-continuous infusion-dosed cefuroxime prophylaxis for the prevention of infections after colorectal surgery. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019 , 38, 357-363	5.3	3
127	Physiologically-Based Pharmacokinetic model for Ciprofloxacin in children with complicated Urinary Tract Infection. <i>European Journal of Pharmaceutical Sciences</i> , 2019 , 128, 171-179	5.1	5
126	Recovery time after oral and maxillofacial ambulatory surgery with dexmedetomidine: an observational study. <i>Clinical Oral Investigations</i> , 2019 , 23, 391-397	4.2	
125	Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter. <i>European Journal of Pharmaceutical Sciences</i> , 2018 , 117, 193-203	5.1	5
124	Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer. <i>European Journal of Pharmaceutical Sciences</i> , 2018 , 115, 296-303	5.1	10
123	Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018 , 366, 96-104	4.7	6
122	The Long Neglected Player: Modeling Tumor Uptake to Guide Optimal Dosing. <i>Clinical Cancer Research</i> , 2018 , 24, 3236-3238	12.9	5
121	Semi-mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and ior \square EPOCIM in New Zealand rabbits. <i>European Journal of Pharmaceutical Sciences</i> , 2018 , 120, 123-132	5.1	
120	A systems pharmacology model for inflammatory bowel disease. <i>PLoS ONE</i> , 2018 , 13, e0192949	3.7	16
119	Optimal dynamic control approach in a multi-objective therapeutic scenario: Application to drug delivery in the treatment of prostate cancer. <i>PLoS Computational Biology</i> , 2018 , 14, e1006087	5	6
118	Precision Medicine Test Is Similar but Faster Than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments. <i>Blood</i> , 2018 , 132, 1493-1493	2.2	
117	Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 379-392	6.2	10
116	Model-Based Reverse Translation Between Veterinary and Human Medicine: The One Health Initiative. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018 , 7, 65-68	4.5	14
115	Advanced Boolean modeling of biological networks applied to systems pharmacology. <i>Bioinformatics</i> , 2017 , 33, 1040-1048	7.2	10
114	Effect of Dexmedetomidine and Propofol on Basal Ganglia Activity in Parkinson Disease: A Controlled Clinical Trial. <i>Anesthesiology</i> , 2017 , 126, 1033-1042	4.3	24
113	Commentary on Pharmacometrics for Immunotherapy. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017 , 6, 8-10	4.5	4
112	Characterizing Gemcitabine Effects Administered as Single Agent or Combined with Carboplatin in Mice Pancreatic and Ovarian Cancer Xenografts: A Semimechanistic Pharmacokinetic/Pharmacodynamics Tumor Growth-Response Model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017 , 360, 445-456	4.7	7
111	A population model to predict progression free survival in breast cancer patients treated with neoadjuvant chemotherapy \square vaccines based on tumour growth inhibition metrics.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e12114-e12114	2.2	

110	Population pharmacokinetic model of lithium and drug compliance assessment. <i>European Neuropsychopharmacology</i> , 2016 , 26, 1868-1876	1.2	7
109	Population pharmacokinetic/pharmacodynamic modelling of the effects of axomadol and its O-demethyl metabolite on pupil diameter and nociception in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 92-107	3.8	5
108	Establishing the Quantitative Relationship Between Lanreotide Autogel [®] , Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors. <i>AAPS Journal</i> , 2016 , 18, 703-12	3.7	12
107	Modeling Respiratory Depression Induced by Remifentanyl and Propofol during Sedation and Analgesia Using a Continuous Noninvasive Measurement of pCO ₂ . <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016 , 356, 563-73	4.7	14
106	Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications. <i>Oncologist</i> , 2016 , 21, 220-32	5.7	24
105	EGF-liposomes promote efficient EGFR targeting in xenograft colocal carcinoma model. <i>Nanomedicine</i> , 2016 , 11, 465-77	5.6	16
104	Population Pharmacokinetic Analysis of Lanreotide Autogel/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 461-73	6.2	7
103	Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model. <i>Oncotarget</i> , 2016 , 7, 76891-76901	3.3	8
102	An ex vivo native environment precision medicine AML test and the correlation with responses to 1st line treatment.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e18510-e18510	2.2	
101	Population Pharmacokinetics of Clarithromycin in Mexican Hospitalized Patients with Respiratory Disease: Evidence for a Reduced Clearance. <i>International Journal of Pharmacology</i> , 2016 , 13, 54-63	0.7	
100	Towards patient stratification and treatment in the autoimmune disease lupus erythematosus using a systems pharmacology approach. <i>European Journal of Pharmaceutical Sciences</i> , 2016 , 94, 46-58	5.1	12
99	Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 1263-73	3.5	13
98	Relation between acute and long-term cognitive decline after surgery: Influence of metabolic syndrome. <i>Brain, Behavior, and Immunity</i> , 2015 , 50, 203-208	16.6	9
97	Validation of a semi-physiological model for caffeine in healthy subjects and cirrhotic patients. <i>European Journal of Pharmaceutical Sciences</i> , 2015 , 73, 57-63	5.1	2
96	Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid. <i>European Journal of Pharmaceutical Sciences</i> , 2015 , 74, 86-94	5.1	4
95	Early Prediction of Disease Progression in Small Cell Lung Cancer: Toward Model-Based Personalized Medicine in Oncology. <i>Cancer Research</i> , 2015 , 75, 2416-25	10.1	8
94	Pharmacokinetic-pharmacodynamic modelling in anaesthesia. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 72-84	3.8	22
93	Population pharmacokinetic modelling of irosustat in postmenopausal women with oestrogen-receptor positive breast cancer incorporating non-linear red blood cell uptake. <i>Pharmaceutical Research</i> , 2015 , 32, 1493-504	4.5	5

92	Can pentylenetetrazole and maximal electroshock rodent seizure models quantitatively predict antiepileptic efficacy in humans?. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2015 , 24, 21-7	3.2	31
91	Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015 , 4, 316-9	4.5	34
90	Sedation-analgesia with propofol and remifentanyl: concentrations required to avoid gag reflex in upper gastrointestinal endoscopy. <i>Anesthesia and Analgesia</i> , 2015 , 121, 90-96	3.9	13
89	Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 630-41	3.8	22
88	ADME Processes in Vaccines and PK/PD Approaches for Vaccination Optimization 2015 , 1-22		
87	Population pharmacokinetic models for cefuroxime and metronidazole used in combination as prophylactic agents in colorectal surgery: Model-based evaluation of standard dosing regimens. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 504-11	14.3	12
86	Semimechanistic cell-cycle type-based pharmacokinetic/pharmacodynamic model of chemotherapy-induced neutropenic effects of diflomotecan under different dosing schedules. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015 , 354, 55-64	4.7	16
85	Tramadol and o-desmethyl tramadol clearance maturation and disposition in humans: a pooled pharmacokinetic study. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 167-78	6.2	35
84	Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities. <i>Clinical Pharmacology and Therapeutics</i> , 2015 , 97, 37-54	6.1	67
83	Population pharmacokinetic (PK) analysis of lanreotide autogel/depot in the treatment of gastroenteropancreatic (GEP) neuroendocrine tumors (NETs): Pooled analysis of four clinical trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 397-397	2.2	1
82	High Correlation Clinical Responses to 1st Line Acute Myeloid Leukemia Treatment with an Ex Vivo Native Environment Precision Medicine Test. <i>Blood</i> , 2015 , 126, 4837-4837	2.2	
81	Semi-mechanistic modelling of the analgesic effect of gabapentin in the formalin-induced rat model of experimental pain. <i>Pharmaceutical Research</i> , 2014 , 31, 593-606	4.5	4
80	A population pharmacodynamic model for lactate dehydrogenase and neuron specific enolase to predict tumor progression in small cell lung cancer patients. <i>AAPS Journal</i> , 2014 , 16, 609-19	3.7	23
79	Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 180-9	5.1	46
78	Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, 305-18	2	24
77	A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2014 , 3, e113	4.5	104
76	Review on modeling anti-antibody responses to monoclonal antibodies. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014 , 41, 523-36	2.7	35
75	Joint population pharmacokinetic/pharmacodynamic model for the heart rate effects at rest and at the end of exercise for cilobradine. <i>Pharmaceutical Research</i> , 2013 , 30, 1110-22	4.5	4

74	Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategies. <i>AAPS Journal</i> , 2013 , 15, 797-807	3-7	22
73	Target-mediated disposition model describing the dynamics of IL12 and IFN γ after administration of a mifepristone-inducible adenoviral vector for IL-12 expression in mice. <i>AAPS Journal</i> , 2013 , 15, 183-94	4-7	3
72	Modeling the influence of the A118G polymorphism in the OPRM1 gene and of noxious stimulation on the synergistic relation between propofol and remifentanyl: sedation and analgesia in endoscopic procedures. <i>Anesthesiology</i> , 2013 , 118, 1395-407	4-3	18
71	Modeling tumor response after combined administration of different immune-stimulatory agents. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013 , 346, 432-42	4-7	17
70	Predicting relapsing-remitting dynamics in multiple sclerosis using discrete distribution models: a population approach. <i>PLoS ONE</i> , 2013 , 8, e73361	3-7	9
69	Pharmacological Profile Of Cytarabine and Idarubicin In Patient Samples (ex vivo) With Newly Diagnosed Acute Myeloid Leukemia Identifies Responders Vs Non Responders. <i>Blood</i> , 2013 , 122, 3923-3923		
68	Personalizing Therapies With Ex Vivo Pharmacological Responses May Uncover The Differences Between IDA-DNR-MIT Among European AML Protocols. <i>Blood</i> , 2013 , 122, 1294-1294	2-2	
67	Pharmacokinetic/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012 , 342, 788-98	4-7	24
66	Application of different methods to formulate PEG-liposomes of oxaliplatin: evaluation in vitro and in vivo. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2012 , 81, 273-80	5-7	34
65	Semi-mechanistic modeling of the interaction between the central and peripheral effects in the antinociceptive response to lumiracoxib in rats. <i>AAPS Journal</i> , 2012 , 14, 904-14	3-7	2
64	Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 70, 239-50	3-5	16
63	Population pharmacokinetic/pharmacodynamic model for the sedative effects of flibanserin in healthy volunteers. <i>Pharmaceutical Research</i> , 2012 , 29, 1518-29	4-5	10
62	Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery. <i>European Journal of Clinical Pharmacology</i> , 2012 , 68, 735-45	2-8	18
61	Pharmacodynamic modeling of the effects of lanreotide Autogel on growth hormone and insulin-like growth factor 1. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 487-98	2-9	9
60	Kinetic and dynamic computational model-based characterization of new proteins in mice: application to interferon alpha linked to apolipoprotein A-I. <i>PLoS ONE</i> , 2012 , 7, e42100	3-7	2
59	Kidney and liver distribution of ochratoxin A in male and female F344 rats. <i>Food and Chemical Toxicology</i> , 2011 , 49, 1935-42	4-7	25
58	Pharmacokinetic/pharmacodynamic evaluation of amoxicillin, amoxicillin/clavulanate and ceftriaxone in the treatment of paediatric acute otitis media in Spain. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2011 , 29, 167-73	0-9	12
57	Modeling the effect of propofol and remifentanyl combinations for sedation-analgesia in endoscopic procedures using an Adaptive Neuro Fuzzy Inference System (ANFIS). <i>Anesthesia and Analgesia</i> , 2011 , 112, 331-9	3-9	30

56	Obesity does not influence the onset and offset of sevoflurane effect as measured by the hysteresis between sevoflurane concentration and bispectral index. <i>Anesthesia and Analgesia</i> , 2011 , 113, 70-6	3.9	10
55	Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies. <i>Investigational New Drugs</i> , 2011 , 29, 984-95	4.3	18
54	Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 1517-27	3.5	7
53	Pharmacokinetic-pharmacodynamic modelling of the analgesic effects of lumiracoxib, a selective inhibitor of cyclooxygenase-2, in rats. <i>British Journal of Pharmacology</i> , 2010 , 159, 176-87	8.6	7
52	Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 inhibitor) and pemetrexed. <i>Clinical Pharmacology and Therapeutics</i> , 2010 , 88, 660-7	6.1	19
51	Feasibility of microdialysis to determine interstitial rocuronium concentration in the muscle tissue of anesthetized neurosurgical patients. <i>Journal of Neurosurgical Anesthesiology</i> , 2010 , 22, 163-9	3	4
50	Modelling the genesis and treatment of cancer: the potential role of physiologically based pharmacodynamics. <i>European Journal of Cancer</i> , 2010 , 46, 21-32	7.5	10
49	Effects of fasting and gender on ochratoxin A toxicokinetics in F344 rats. <i>Food and Chemical Toxicology</i> , 2010 , 48, 3159-66	4.7	17
48	Incorporating physiological and biochemical mechanisms into pharmacokinetic-pharmacodynamic models: a conceptual framework. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010 , 106, 2-12	3.1	16
47	Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 785-95	3.5	18
46	A semi-physiological-based pharmacokinetic/pharmacodynamic model to describe the effects of topotecan on b-lymphocyte lineage cells. <i>Pharmaceutical Research</i> , 2010 , 27, 431-41	4.5	3
45	Population in vitro-in vivo correlation model for pramipexole slow-release oral formulations. <i>Pharmaceutical Research</i> , 2010 , 27, 340-9	4.5	12
44	Gene therapy: a pharmacokinetic/pharmacodynamic modelling overview. <i>Pharmaceutical Research</i> , 2010 , 27, 1487-97	4.5	37
43	Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 4816-24	5.9	39
42	Biopharmaceutic and pharmacodynamic modeling of the in vitro antiproliferative effect of new controlled delivery systems of cisplatin. <i>European Journal of Pharmaceutical Sciences</i> , 2009 , 37, 341-50	5.1	8
41	Semi-mechanistic pharmacodynamic modelling of gene expression and silencing processes. <i>European Journal of Pharmaceutical Sciences</i> , 2009 , 37, 418-26	5.1	13
40	Performance in population models for count data, part I: maximum likelihood approximations. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2009 , 36, 353-66	2.7	20
39	Modelling overdispersion and Markovian features in count data. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2009 , 36, 461-77	2.7	29

38	A different kinetic profile of ochratoxin A in mature male rats. <i>Food and Chemical Toxicology</i> , 2009 , 47, 1921-7	4.7	29
37	Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months. <i>Clinical Pharmacokinetics</i> , 2009 , 48, 51-62	6.2	20
36	Semi-mechanistic description of the in-vitro antiproliferative effect of different antitumour agents. <i>Journal of Pharmacy and Pharmacology</i> , 2008 , 60, 77-82	4.8	3
35	Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 173-80	6.2	48
34	Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. <i>European Journal of Cancer</i> , 2008 , 44, 142-50	7.5	173
33	The influence of age on the dynamic relationship between end-tidal sevoflurane concentrations and bispectral index. <i>Anesthesia and Analgesia</i> , 2008 , 107, 1566-72	3.9	29
32	Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antinociceptive response in the presence of competitive antagonism: the interaction between tramadol and its active metabolite on micro-opioid agonism and monoamine reuptake inhibition, in the rat. <i>Pharmaceutical Research</i> , 2008 , 25, 1789-97	4.5	12
31	Pharmacokinetic-pharmacodynamic modeling of the influence of chronic phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery. <i>European Journal of Clinical Pharmacology</i> , 2008 , 64, 795-806	2.8	18
30	Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. <i>Journal of Clinical Pharmacology</i> , 2007 , 47, 371-82	2.9	73
29	Tadalafil population pharmacokinetics in patients with erectile dysfunction. <i>European Journal of Clinical Pharmacology</i> , 2007 , 63, 583-90	2.8	14
28	Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2006 , 57, 727-35	3.5	35
27	Intrahepatic injection of recombinant adeno-associated virus serotype 2 overcomes gender-related differences in liver transduction. <i>Human Gene Therapy</i> , 2006 , 17, 601-10	4.8	25
26	Modelling the anti-migraine effects of BIBN 4096 BS: a new calcitonin gene-related peptide receptor antagonist. <i>Clinical Pharmacokinetics</i> , 2006 , 45, 715-28	6.2	13
25	Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. <i>British Journal of Clinical Pharmacology</i> , 2006 , 62, 527-37	3.8	95
24	Dealing with time-dependent pharmacokinetics during the early clinical development of a new leukotriene B4 synthesis inhibitor. <i>Pharmaceutical Research</i> , 2006 , 23, 1533-42	4.5	13
23	Population pharmacokinetic/pharmacodynamic modelling of the analgesic effects of tramadol in pediatrics. <i>Pharmaceutical Research</i> , 2006 , 23, 2014-23	4.5	534
22	Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. <i>Metabolism: Clinical and Experimental</i> , 2005 , 54, 1276-81	12.7	33
21	Population pharmacokinetic modelling of BIBN 4096 BS, the first compound of the new class of calcitonin gene-related peptide receptor antagonists. <i>European Journal of Pharmaceutical Sciences</i> , 2004 , 22, 287-95	5.1	5

20	Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations. <i>Pharmaceutical Research</i> , 2004 , 21, 567-73	4.5	12
19	Population dose-response model for tadalafil in the treatment of male erectile dysfunction. <i>Pharmaceutical Research</i> , 2004 , 21, 1463-70	4.5	10
18	Modelling and simulation in the development and use of anti-cancer agents: an underused tool?. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2004 , 31, 419-40	2.7	13
17	Intestinal absorption of penclomedine from lipid vehicles in the conscious rat: contribution of emulsification versus digestibility. <i>International Journal of Pharmaceutics</i> , 2004 , 270, 109-18	6.5	65
16	Pharmacokinetic/pharmacodynamic modeling of the antinociceptive effects of (+)-tramadol in the rat: role of cytochrome P450 2D activity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003 , 305, 710-8	4.7	40
15	Modeling of the sedative and airway obstruction effects of propofol in patients with Parkinson disease undergoing stereotactic surgery. <i>Anesthesiology</i> , 2002 , 97, 1378-86	4.3	33
14	Testosterone and estradiol modulate TNF-alpha-induced expression of adhesion molecules in endothelial cells. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 2002 , 24, 125-30		21
13	Pharmacokinetic-pharmacodynamic modeling in anesthesia. <i>International Congress Series</i> , 2001 , 1220, 89-97		1
12	Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: application to moxonidine. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 68, 18-27	6.1	6
11	Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 898-904	5.9	26
10	Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen. <i>Clinical Pharmacokinetics</i> , 2000 , 38, 505-18	6.2	35
9	Simultaneous determination of tramadol and its major active metabolite O-demethyltramadol by high-performance liquid chromatography with electrochemical detection. <i>Biomedical Applications</i> , 1999 , 724, 83-9		36
8	Methadone: a review of its pharmacokinetic/pharmacodynamic properties. <i>Journal of Pharmacological and Toxicological Methods</i> , 1999 , 42, 61-6	1.7	124
7	Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 64, 106-16	6.1	24
6	Serum protein binding of lerisetron, a novel specific 5HT3 antagonist, in patients with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1998 , 42, 418-22	3.5	8
5	Pharmacokinetic-pharmacodynamic modeling of mivacurium in rats. <i>Journal of Pharmaceutical Sciences</i> , 1997 , 86, 252-6	3.9	1
4	Quantitative analysis of temazepam in plasma by capillary gas chromatography: Application to pharmacokinetic studies in rats. <i>Chromatographia</i> , 1997 , 44, 169-171	2.1	1
3	A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex. <i>Clinical Pharmacology and Therapeutics</i> , 1997 , 61, 70-82	6.1	10

- | | | | |
|---|--|-----|----|
| 2 | Resistance to atracurium in rats with experimental inflammation: role of protein binding. <i>Acta Anaesthesiologica Scandinavica</i> , 1995 , 39, 1019-23 | 1.9 | 12 |
| 1 | Tenoxicam pharmacokinetics in rats: a population model. <i>Journal of Pharmaceutical Sciences</i> , 1995 , 84, 1482-7 | 3.9 | 6 |